Weybosset Research & Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$621K |
| 2 |
Constellation Brands
STZ
|
+$541K |
| 3 |
Hexcel
HXL
|
+$503K |
| 4 |
Aptiv
APTV
|
+$404K |
| 5 |
Procter & Gamble
PG
|
+$252K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$54.3M |
| 2 |
Copart
CPRT
|
+$477K |
| 3 |
Pfizer
PFE
|
+$410K |
| 4 |
McDonald's
MCD
|
+$359K |
| 5 |
3M
MMM
|
+$299K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 35.92% |
| 2 | Technology | 13.5% |
| 3 | Financials | 13.41% |
| 4 | Healthcare | 9.02% |
| 5 | Consumer Discretionary | 8.83% |
Similar funds
Weybosset Research & Management's Q2 2020 Portfolio in Review
As of Q2 2020, Weybosset Research & Management held 57 positions worth $171M, up 22% from $140M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Weybosset Research & Management withdrew a net $54.9M in Q2 2020, closing 6 positions and reducing 23 holdings. Its most notable exit was Pfizer, an estimated $410K position sold in full.
By sector, the portfolio is most concentrated in Industrials at 36% of assets, down from 37% a quarter earlier, followed by Technology and Financials.
Against the trend, Weybosset Research & Management opened a new position in Constellation Brands worth $330K.
- Weybosset Research & Management's largest Q2 2020 buy was Constellation Brands: 3,250 shares worth $330K.
- Weybosset Research & Management added most to JPMorgan Chase in Q2 2020, an estimated $621K increase.
- Weybosset Research & Management's biggest Q2 2020 reduction was Berkshire Hathaway Class A, cutting an estimated $54.3M.
- Weybosset Research & Management fully exited Pfizer in Q2 2020, selling an estimated $410K.
- Weybosset Research & Management's ten largest holdings make up 54% of its $171M portfolio in Q2 2020.
- Weybosset Research & Management opened 4 new positions and closed 6 in Q2 2020.
- Weybosset Research & Management's portfolio value rose 22% quarter-over-quarter to $171M.
Based on Weybosset Research & Management's 13F filing for Q2 2020, filed 22 Jul 2020.